Why is "MTOR inhibitors" trending?

Search Interest Perspective

• Targeting the 4EBP1/HSP90β/Nrf2 axis sensitizes β-catenin-mutant hepatocellular carcinoma to mTOR inhibitors via ferroptosis induction - EurekAlert!
• Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β‐Blockers to PI3K/AKT/mTOR Inhibitors - Wiley Online Library
• ESMO–ESTRO Consensus on Radiotherapy and Targeted Drugs - Oncodaily
• The mTOR Inhibitors Lifespan Project Enters Next Phase - Lifespan Research Institute
• Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors - CancerNetwork
• How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia? - Haematologica
• Targeting the biology of aging with mTOR inhibitors - Nature
• Pharmacological mTOR inhibitors in ameliorating Alzheimer’s disease: current review and perspectives - Frontiers
• Why can't mTOR inhibitors kill cancer? | News - UT Health San Antonio
• Targeted Treatments for a Type of Pancreatic Cancer: Rapamycin and Other mTOR Inhibitors - National Cancer Institute (.gov)
• Considering Cost and Toxicity Choosing Between CDK4/6 and mTOR Inhibitors for the Treatment of Breast Cancer - ASCO Daily News
• Optimal Management of Side Effects Associated With PIK3CA and mTOR Inhibitors - Medscape
• Researchers Uncover Clues to Treating Rare Thyroid Cancer - Cleveland Clinic
• PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer - Nature
• Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives - Frontiers
• OBGYN - obgyn.onlinelibrary.wiley.com
• Considerations Regarding Public Use of Longevity Interventions - Frontiers
• CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors - Nature
• Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment - Frontiers
• Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells - Nature
• Managing Side Effects of mTOR Inhibitors in Cancer - Cure Today
• Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors - PR Newswire
• Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations - Nature
• Hematological toxicity of mTOR inhibitors is mild and dose-dependent in patients with tuberous sclerosis and subependymal giant cell astrocytoma | Urbański | Acta Haematologica Polonica - Via Medica Journals
• mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3 - PNAS
• Bivalent mTOR inhibitors — the next generation - Nature
• Bifunctional drug could treat tumors resistant to current mTOR inhibitors [PreClinical] - 2 Minute Medicine
• Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges - Wiley Online Library
• Advancements in the Treatment of Malignant PEComas with mTOR Inhibitors - MDEdge
• Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - onclive.com
• Another use for mTOR inhibitors: Preserving vanishing bones in Gorham-Stout syndrome - Boston Children's Answers
• Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors - Nature
• mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? - The Lancet
• Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research - Nature
• Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease - Nature
• Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays - Nature
• Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer - Wiley Online Library
• Application of mTOR inhibitors as first line therapy for tuberous sclerosis-associated kidney disease - Cardiff University
• Early switch from calcineurin inhibitors to mTOR inhibitors leads to improved renal graft function - Nature
• Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma - Nature
• Predicted mechanisms of resistance to mTOR inhibitors - Nature
• Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR Inhibitors - EurekAlert!
• Ex pression of Concern: Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells | PLOS One - PLOS
• LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro - Nature
• Managing mTOR Inhibitor Induced Adverse Events - onclive.com
• Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors | British Journal of Cancer - Nature
• Mammalian target of rapamycin (mTOR) inhibitors in solid tumours - pharmaceutical-journal.com
• Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies - Frontiers
• Skin Toxicity Caused by Sequential Treatment with PD-1 Inhibitor and mTOR Inhibitor - EMJ
• Staying a Step Ahead of Cancer - HHMI
• Alterations in PTEN Insufficient to Predict Sensitivity to Drugs Targeting PI3K/mTOR Pathway - The ASCO Post
• The effect of treatment with mTOR inhibitors on footpad swelling of L major -infected mice. - PLOS
• Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models - Nature
• ‘Suspended’ mouse embryos open new research paths to reproduction, cancer and more - Fierce Biotech
• Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy - Zhao - 2023 - Brain and Behavior - Wiley Online Library
• Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stents—Brief Report - American Heart Association Journals
• Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors - Nature
• mTOR Inhibitors Market Size is Estimated to Reach USD 9,445 Million by 2030 - openpr.com
• Huge Investment in mTOR Inhibitors Market Expected to Witness - openpr.com